Xipere for Suprachoroidal Use Approved for Macular Edema Associated With Uveitis
The approval was based on data from the pivotal phase 3 PEACHTREE trial, the phase 3 MAGNOLIA study, and the open-label safety AZALEA trial.
The approval was based on data from the pivotal phase 3 PEACHTREE trial, the phase 3 MAGNOLIA study, and the open-label safety AZALEA trial.
With Luminopia One, patients watch therapeutically modified TV shows and movies to improve their vision within a virtual reality headset.
The application is supported by data from the phase 2 IMCgp100-202 trial that assessed tebentafusp in 378 HLA-A*02:01-positive adults with previously untreated metastatic uveal melanoma.
The FDA has granted Orphan Drug designation to ADX-2191 (methotrexate for intravitreal injection) for the treatment of retinitis pigmentosa.
The BLA submission is based on positive results across four phase 3 studies in wet AMD and DME.
ALK-001 is an oral, once daily, chemically-modified form of vitamin A.
The approval was based on data from two randomized, multicenter, double-masked, vehicle-controlled trials that evaluated the efficacy and safety of Verkazia in patients with VKC.
Ischemic optic neuropathies are the most common acute optic nerve pathology in patients older than 50 years of age.
Arkadiy Yadgarov, MD, of Omni Eye Services of Atlanta, shows how new options in glaucoma management can help ophthalmology overcome patient noncompliance.
Previously unrecognized pathogenic mechanisms involving ocular contact dermatitis has driven new approaches to control the inflammatory process.